Tumor Co-Expression of Progranulin and Sortilin as a Prognostic Biomarker in Breast Cancer

The authors explored how co-expression of progranulin and sortilin was associated with established clinical markers by analyzing a tissue microarray including 560 randomized premenopausal breast cancer patients receiving either two years of tamoxifen treatment or no adjuvant treatment, with a median follow-up time of 28 years.